Patents by Inventor Andrei W. Konradi

Andrei W. Konradi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF
    Publication number: 20210340105
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: July 8, 2021
    Publication date: November 4, 2021
    Applicant: Cortexyme, Inc.
    Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Casey C. Lynch
  • PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND AMINO GROUP
    Publication number: 20210275510
    Abstract: Described herein are pyridine derivatives substituted by heterocycle and amino groups and pharmaceutical compositions comprising said compounds. The disclosed compounds are antifungal agents. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.
    Type: Application
    Filed: June 24, 2019
    Publication date: September 9, 2021
    Inventors: Andrei W. KONRADI, Jonathan A. COVEL, Michael GREY
  • OXADIAZOLE COMPOUNDS
    Publication number: 20210238154
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Application
    Filed: May 15, 2019
    Publication date: August 5, 2021
    Inventors: Andrei W. KONRADI, Tracy Tzu-Ling Tang LIN
  • Aminopyridine compounds and methods for the preparation and use thereof
    Patent number: 11059786
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: July 13, 2021
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Robert A. Galemmo, Jr., Casey C. Lynch
  • KETONE INHIBITORS OF LYSINE GINGIPAIN
    Publication number: 20210053908
    Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
    Type: Application
    Filed: June 11, 2020
    Publication date: February 25, 2021
    Applicant: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
  • INHIBITORS OF LYSINE GINGIPAIN
    Publication number: 20210017167
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 4, 2020
    Publication date: January 21, 2021
    Applicant: Cortexyme, Inc.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Prodrugs of phenolic TRPV1 agonists
    Patent number: 10851123
    Abstract: Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: December 1, 2020
    Assignee: CONCENTRIC ANALGESICS, INC.
    Inventors: Craig Husfeld, Andrei W. Konradi
  • BENZOSULFONYL COMPOUNDS
    Publication number: 20200354325
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Application
    Filed: August 20, 2018
    Publication date: November 12, 2020
    Inventors: Andrei W. KONRADI, Tracy Tzu-Ling Tang LIN
  • BICYCLIC COMPOUNDS
    Publication number: 20200347009
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Application
    Filed: April 15, 2020
    Publication date: November 5, 2020
    Inventors: Andrei W. KONRADI, Tracy Tzu-Ling Tang LIN
  • INHIBITORS OF JUN N-TERMINAL KINASE
    Publication number: 20200277285
    Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
    Type: Application
    Filed: May 12, 2020
    Publication date: September 3, 2020
    Applicant: IMAGO PHARMACEUTICALS, INC.
    Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
  • Ketone inhibitors of lysine gingipain
    Patent number: 10730826
    Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 4, 2020
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Robert A. Galemmo, Jr., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
  • Inhibitors of lysine gingipain
    Patent number: 10676470
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: June 9, 2020
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF
    Publication number: 20200148642
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 14, 2020
    Applicant: Cortexyme, Inc.
    Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Casey C. Lynch
  • NON-FUSED TRICYCLIC COMPOUNDS
    Publication number: 20200062721
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Application
    Filed: May 2, 2018
    Publication date: February 27, 2020
    Inventors: Andrei W. KONRADI, Tracy Tzu-Ling Tang LIN
  • INHIBITORS OF JUN N-TERMINAL KINASE
    Publication number: 20200039972
    Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
    Type: Application
    Filed: October 15, 2019
    Publication date: February 6, 2020
    Applicant: IMAGO PHARMACEUTICALS, INC.
    Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
  • INHIBITORS OF LYSINE GINGIPAIN
    Publication number: 20190322659
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 30, 2019
    Publication date: October 24, 2019
    Applicant: Cortexyme, Inc.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • KETONE INHIBITORS OF LYSINE GINGIPAIN
    Publication number: 20190210960
    Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 11, 2019
    Applicant: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
  • INHIBITORS OF JUN N-TERMINAL KINASE
    Publication number: 20190194176
    Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Applicant: IMAGO PHARMACEUTICALS, INC.
    Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
  • PRODRUGS OF PHENOLIC TRPV1 AGONISTS
    Publication number: 20190055272
    Abstract: Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.
    Type: Application
    Filed: February 22, 2017
    Publication date: February 21, 2019
    Inventors: Craig HUSFELD, Andrei W. KONRADI
  • INHIBITORS OF JUN N-TERMINAL KINASE
    Publication number: 20180037577
    Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
    Type: Application
    Filed: October 18, 2017
    Publication date: February 8, 2018
    Applicant: IMAGO PHARMACEUTICALS, INC.
    Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH